Track the HALOZYME THERAPEUTICS INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €11.7bn. The latest transaction was filed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Torley Helen. Every trade is accessible without an account.
14
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HALOZYME THERAPEUTICS INC Buy (bullish), based on 9 analysts. Average price target: US$99.56.
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,465 of 29,053 companies
58.5
score / 100
Value
40
Quality
77
FCF yld3.0%
Earn yld2.6%
EV/EBITDA24.8x
ROE174%
Gross mgn84%
Net mgn23%
Debt/EBITDA3.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HALOZYME THERAPEUTICS INC is a biopharmaceutical company focused on developing enzyme-based therapies to enhance drug delivery. It is listed on the NASDAQ under the ticker symbol HALO.